Samsung Bioepis Submits FDA Application for Keytruda Biosimilar SB27
Samsung Bioepis submitted a new drug application to the US FDA for its Keytruda biosimilar SB27.
Samsung Bioepis submitted a new drug application to the US FDA for its Keytruda biosimilar SB27.